Korro Bio, Inc.

Korro Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes genetic medicines based on RNA editing for rare and highly prevalent diseases in the United States. Its lead product candidate, KRRO-121, is being developed for hyperammonemia. The company uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA, to generate differentiated RNA editing product candidates. It is also developing programs for Parkinson's disease, amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Founded in 2018, the company is based in Cambridge, Massachusetts.